Tags

Type your tag names separated by a space and hit enter

Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Diabetes Metab Res Rev 2008 May-Jun; 24(4):286-93DM

Abstract

Chronic complications of type 2 diabetes, in particular, macrovascular complications, confer substantial morbidity and mortality and adversely affect a patient's quality of life. Early intensive intervention to control cardiovascular risk factors is essential in clinical management. Atherogenic dyslipidaemia characterized by elevated triglycerides, a low level of high-density lipoprotein cholesterol (HDL-C), and an increase in the preponderance of small, dense low-density lipoprotein (LDL) particles, is a key modifiable risk factor for macrovascular diabetic complications. Lowering low-density lipoprotein cholesterol (LDL-C) with a statin (or the combination of statin and ezetimibe) is the main focus for reducing cardiovascular risk in patients with diabetes. However, statins fail to address the residual cardiovascular risk associated with low HDL-C. Fibrates are effective against all components of the atherogenic dyslipidaemia associated with type 2 diabetes. Secondary analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study suggest a role for early treatment with fenofibrate in improving cardiovascular risk reduction in type 2 diabetes and provide safety data supporting the use of fenofibrate in combination with a statin. Data from the FIELD study suggest that fenofibrate may also have potential to impact on microvascular diabetic complications associated with type 2 diabetes. Data are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to evaluate the outcome benefits of combining fenofibrate with a statin in patients with type 2 diabetes. Finally, in view of divergent study results and outstanding data, assessment of the risk of the individual with type 2 diabetes is mandatory to assist clinical decision-making when initiating lipid therapy.

Authors+Show Affiliations

Department of Internal Medicine, St Nikolaus-Stiftshospital, Andernach Teaching Hospital, University of Bonn, Germany. armin.steinmetz@stiftshospital-andernach.de

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18273835

Citation

Steinmetz, Armin. "Lipid-lowering Therapy in Patients With Type 2 Diabetes: the Case for Early Intervention." Diabetes/metabolism Research and Reviews, vol. 24, no. 4, 2008, pp. 286-93.
Steinmetz A. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. Diabetes Metab Res Rev. 2008;24(4):286-93.
Steinmetz, A. (2008). Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. Diabetes/metabolism Research and Reviews, 24(4), pp. 286-93. doi:10.1002/dmrr.806.
Steinmetz A. Lipid-lowering Therapy in Patients With Type 2 Diabetes: the Case for Early Intervention. Diabetes Metab Res Rev. 2008;24(4):286-93. PubMed PMID: 18273835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. A1 - Steinmetz,Armin, PY - 2008/2/15/pubmed PY - 2008/8/8/medline PY - 2008/2/15/entrez SP - 286 EP - 93 JF - Diabetes/metabolism research and reviews JO - Diabetes Metab. Res. Rev. VL - 24 IS - 4 N2 - Chronic complications of type 2 diabetes, in particular, macrovascular complications, confer substantial morbidity and mortality and adversely affect a patient's quality of life. Early intensive intervention to control cardiovascular risk factors is essential in clinical management. Atherogenic dyslipidaemia characterized by elevated triglycerides, a low level of high-density lipoprotein cholesterol (HDL-C), and an increase in the preponderance of small, dense low-density lipoprotein (LDL) particles, is a key modifiable risk factor for macrovascular diabetic complications. Lowering low-density lipoprotein cholesterol (LDL-C) with a statin (or the combination of statin and ezetimibe) is the main focus for reducing cardiovascular risk in patients with diabetes. However, statins fail to address the residual cardiovascular risk associated with low HDL-C. Fibrates are effective against all components of the atherogenic dyslipidaemia associated with type 2 diabetes. Secondary analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study suggest a role for early treatment with fenofibrate in improving cardiovascular risk reduction in type 2 diabetes and provide safety data supporting the use of fenofibrate in combination with a statin. Data from the FIELD study suggest that fenofibrate may also have potential to impact on microvascular diabetic complications associated with type 2 diabetes. Data are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to evaluate the outcome benefits of combining fenofibrate with a statin in patients with type 2 diabetes. Finally, in view of divergent study results and outstanding data, assessment of the risk of the individual with type 2 diabetes is mandatory to assist clinical decision-making when initiating lipid therapy. SN - 1520-7552 UR - https://www.unboundmedicine.com/medline/citation/18273835/Lipid_lowering_therapy_in_patients_with_type_2_diabetes:_the_case_for_early_intervention_ L2 - https://doi.org/10.1002/dmrr.806 DB - PRIME DP - Unbound Medicine ER -